- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT02840747
Dépôt de tissus : protocole de collecte du CTCL
Un dépôt de tissus pour la collecte d'échantillons de patients atteints de lymphome cutané à cellules T et de volontaires sains
This document is a protocol for a non-interventional human research study in which the investigator hopes to better understand the changes that take place in T cells in Cutaneous T-cell lymphoma (CTCL). The purpose of this study is to establish a protocol for the collection and storage of tissue samples from patients with CTCL for future research studies. Collection and storage of tissue samples from control patients will also be carried out.
Aperçu de l'étude
Statut
Description détaillée
CTCL is a heterogeneous group of non-Hodgkin's lymphomas characterized by chronic inflammation and accumulation of malignant T cells in the skin. In order to carry out research to expand the knowledge and develop more effective treatments, tissue samples from CTCL patients with presumed or known disorders are required and tissue samples from control patients will be required to compare the differences between affected and healthy populations.
Scientists will be able to test new ideas and new technologies that are not apparent or available at the present moment from this tissue repository in the future. This type of information will thus be of great advantage to future patients with these diseases.
Type d'étude
Inscription (Estimé)
Contacts et emplacements
Coordonnées de l'étude
- Nom: Larisa J. Geskin, MD
- E-mail: ljg2145@cumc.columbia.edu
Sauvegarde des contacts de l'étude
- Nom: Brigit Lapolla
- E-mail: bl2963@cumc.columbia.edu
Lieux d'étude
-
-
New York
-
New York, New York, États-Unis, 10032
- Recrutement
- Columbia University Irving Medical Center
-
Contact:
- Brigit Lapolla
- E-mail: bl2963@cumc.columbia.edu
-
Contact:
- Larisa J. Geskin, MD
- Numéro de téléphone: 212-305-5293
- E-mail: ljg2145@cumc.columbia.edu
-
Chercheur principal:
- Larisa J. Geskin, MD
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
Méthode d'échantillonnage
Population étudiée
This protocol is for the collection of biological specimens from patients who fall into the following three groups:
- Patients with diagnosis of cutaneous T cell lymphoma (diagnosed according to the WHO-EORTC criteria)
- Patients with benign dermatoses, including but not limited to psoriasis, eczema, and dermatitis.
- Healthy controls
La description
Inclusion Criteria:
- Patients with CTCL or Lymphomatoid Papulosis (LYP): a clinical or histologic diagnosis of a) newly diagnosed, b) progressive, or c) relapsed CTCL or LYP who are initiating or changing therapy.
- Patients with Sézary Syndrome (SS) or stage IV B CTCL as defined by blood involvement on flow cytometry or morphology: (1) ≥1000/μL Sézary cells by morphology; (2) Cluster of differentiation 4 (CD4)/cluster of differentiation 8 (CD8) ratio ≥10; (3) CD4+cluster of differentiation 7 (CD7)- cells ≥40 percent; (4) or CD4+cluster of differentiation 26 (CD26)- cells ≥30 percent.
- Ability to understand and willing to sign a willing informed consent document.
- Age ≥ 18 years.
Inclusion Criteria for Age and Sex Matched Controls:
- Matched for sex, and age +/- 10 years.
- Ability to sign informed consent document.
- Patients with or without benign inflammatory skin conditions including, but not limited to, eczema, psoriasis, or dermatitis or Patients without skin conditions requiring treatment with systemic immunosuppressive, biologic, or chemotherapeutic agents.
Exclusion Criteria:
- Patients with a history of previous lymphoma other than CTCL or SS or LYP.
- Medical illnesses with potential suppressive or activating impact on immune and bowel function as judged by the investigator.
- Current, viable pregnancy.
- Anemia with a documented hemoglobin laboratory value of <7.5 g/dl within the past 6 months.
Exclusion Criteria for Age and Sex Matched Controls:
- Previous history of CTCL, SS, LYP, or any lymphoma.
- Previous history of Human Immunodeficiency Virus (HIV) infection.
- Anemia with a documented hemoglobin laboratory value of <7.5 g/dl within the past 6 months.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Modèles d'observation: OTHER
- Perspectives temporelles: PROSPECTIVE
Cohortes et interventions
Groupe / Cohorte |
|---|
|
Patients with CTCL
Skin biopsies, blood samples, skin swabs, nasal swabs, cheek epithelium swabs, fecal samples and urine samples may be collected from patients with CTCL (according to World Health Organization-European Organization for Research and Treatment of Cancer (WHO-EORTC) criteria). |
|
Patients with benign dermatoses
Skin biopsies, blood samples, skin swabs, nasal swabs, cheek epithelium swabs, fecal samples and urine samples may be collected from patients with benign dermatoses, including but not limited to conditions such as eczema, psoriasis, and dermatitis. |
|
Healthy Controls
Skin biopsies, blood samples, skin swabs, nasal swabs, cheek epithelium swabs, fecal samples and urine samples may be collected from healthy volunteers. |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Number of biological specimen collections
Délai: 2 years
|
This is a collection protocol to establish a tissue repository for samples from patients with CTCL. |
2 years
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Chercheur principal: Larisa J. Geskin, MD, Columbia University
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimé)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- AAAQ8751
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .